leisure time -WSS

leisure time

author：leisure time 2025-09-06 03:55:07 - browse：2

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Supreme Court strikes down use of affirmative action

focus

WSS

Hepatitis C has a cure — but many Americans still lack access to it

Continuity nursing helped my family in our darkest PICU moments

Drug repurposing or repositioning? The language matters

Timeline: Special counsel's investigation into Trump's handling of classified documents

Dobbs anniversary: the lost opportunity of abortion as health care

Novo acquires Inversago for up to $1 billion

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How to save PrEP access — and even expand it

Guidelines to prevent youth baseball injuries need more muscle

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Duchenne breakthrough therapy leaves behind pioneering families

Who are the detained American citizens released from prison in Iran?

Virginia high school admissions case could be legal follow

Faced with fears of OxyContin misuse, sales reps touted its safety

Affirmative action in medical school literally saved lives

Covid's long

focus

Moonlake's readout produced a cash windfall. Risks remain

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Newly revealed memo details efforts to keep Trump in power following election loss

Affirmative action in medical school literally saved lives

Duchenne breakthrough therapy leaves behind pioneering families

Guidelines to prevent youth baseball injuries need more muscle

hotspot

entertainment

focus

hotspot